KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EPS (Basic): 2012-2024

Historic EPS (Basic) for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to -$4.08.

  • Travere Therapeutics' EPS (Basic) rose 141.43% to $0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.03, marking a year-over-year increase of 77.36%. This contributed to the annual value of -$4.08 for FY2024, which is 19.53% up from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' EPS (Basic) is -$4.08, which was up 19.53% from -$5.07 recorded in FY2023.
  • Travere Therapeutics' EPS (Basic)'s 5-year high stood at -$3.56 during FY2020, with a 5-year trough of -$5.20 in FY2022.
  • Its 3-year average for EPS (Basic) is -$4.78, with a median of -$5.07 in 2023.
  • Its EPS (Basic) has fluctuated over the past 5 years, first plummeted by 43.25% in 2022, then increased by 19.53% in 2024.
  • Yearly analysis of 5 years shows Travere Therapeutics' EPS (Basic) stood at -$3.56 in 2020, then dropped by 1.97% to -$3.63 in 2021, then crashed by 43.25% to -$5.20 in 2022, then climbed by 2.50% to -$5.07 in 2023, then climbed by 19.53% to -$4.08 in 2024.